biostudies-literatureUnknown9(8)Lowentritt BHBlue Earth Diagnostics<h4>Purpose</h4>¹⁸F-Flotufolastat (¹⁸F-rhPSMA-7.3) is a newly approved prostate-specific membrane antigen targeting radiopharmaceutical for diagnostic imaging of prostate cancer (PCa). SPOTLIGHT (National Clinical Trials 04186845) evaluated ¹⁸F-flotufolastat in men with suspected PCa recurrence. Here, we present results of predefined exploratory endpoints from SPOTLIGHT to evaluate the impact of clinical factors on ¹⁸F-flotufolastat detection rates (DR).<h4>Methods and materials</h4>The impact of baseline prostate-specific antigen (PSA), PSA doubling time (PSAdt), and International Society of Urologic Pathology Grade Group (GG) on ¹⁸F-flotufolastat DR was evaluated among all SPOTLIGHT patients with an evaluable scan, with DR stratifiedAdvances in radiation oncology101532https://www.ebi.ac.uk/biostudies/studies/S-EPMC11298587biostudies-literatureImpact of Clinical Factors on ¹⁸F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study.PMC11298587Chapin BFHelfand BTChau AUchio EMLowentritt BHSPOTLIGHT Study GroupMichalski JMMorris MASchuster DMDavis PJani ABfalseImpact of Clinical Factors on ¹⁸F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study.<h4>Purpose</h4>¹⁸F-Flotufolastat (¹⁸F-rhPSMA-7.3) is a newly approved prostate-specific membrane antigen targeting radiopharmaceutical for diagnostic imaging of prostate cancer (PCa). SPOTLIGHT (National Clinical Trials 04186845) evaluated ¹⁸F-flotufolastat in men with suspected PCa recurrence. Here, we present results of predefined exploratory endpoints from SPOTLIGHT to evaluate the impact of clinical factors on ¹⁸F-flotufolastat detection rates (DR).<h4>Methods and materials</h4>The impact of baseline prostate-specific antigen (PSA), PSA doubling time (PSAdt), and International Society of Urologic Pathology Grade Group (GG) on ¹⁸F-flotufolastat DR was evaluated among all SPOTLIGHT patients with an evaluable scan, with DR stratified2024-01-01T00:00:00Z2024 Aug2025-04-22T21:49:21.28Z2024-11-09T01:55:08.406ZS-EPMC112985873910487510.1016/j.adro.2024.101532